New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:15 EDTZIOP, XONZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
News For ZIOP;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
07:56 EDTXONIntrexon price target raised to $70 from $55 at Wunderlich
Subscribe for More Information
July 24, 2015
11:18 EDTZIOPZiopharm announces Orphan Drug Designation for Ad-RTS-hIL-12
Subscribe for More Information
08:02 EDTZIOPZiopharm granted orphan status for glioma treatment
Subscribe for More Information
July 21, 2015
08:06 EDTXONIntrexon names Jack Bobo as Chief Communications Officer
Subscribe for More Information
06:13 EDTZIOPZiopharm implied volatility of 71 at lower end of index mean range
Subscribe for More Information
July 20, 2015
08:10 EDTXONFibrocell Science, Intrexon file IND for FCX-007
Fibrocell Science (FCSC) and Intrexon (XON) announced the submission of an Investigational New Drug, or IND, Application with the FDA for FCX-007, Fibrocell's lead orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB.
06:22 EDTZIOPZiopharm implied volatility of 76 at lower end of index mean range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use